Effects of Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of Tamoxifen

@inproceedings{Schultink2015EffectsOP,
  title={Effects of Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of Tamoxifen},
  author={Aurelia H. M. de Vries Schultink and Wilbert Zwart and Sabine Linn and Jos H. Beijnen and Alwin D. R. Huitema},
  booktitle={Clinical pharmacokinetics},
  year={2015}
}
The antiestrogenic drug tamoxifen is widely used in the treatment of estrogen receptor-α-positive breast cancer and substantially decreases recurrence and mortality rates. However, high interindividual variability in response is observed, calling for a personalized approach to tamoxifen treatment. Tamoxifen is bioactivated by cytochrome P450 (CYP) enzymes such as CYP2B6, CYP2C9, CYP2C19, CYP2D6 and CYP3A4/5, resulting in the formation of active metabolites, including 4-hydroxy-tamoxifen and… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 11 extracted citations

Toward precision medicine of breast cancer

Theoretical Biology and Medical Modelling • 2016
View 7 Excerpts
Highly Influenced

References

Publications referenced by this paper.
Showing 1-10 of 69 references

Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes.

Clinical pharmacology and therapeutics • 2011
View 19 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…